GRGDSPK

CAT:
804-HY-P0322-01
Size:
1 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
GRGDSPK - image 1

GRGDSPK

  • Description:

    GRGDSPK (EMD 56574) is a peptide incluing Arg-Gly-Asp (RGD) . GRGDSPK (EMD 56574) is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK is used to study the role of integrins in bone formation and resorption[1][2].
  • Product Name Alternative:

    EMD 56574
  • UNSPSC:

    12352209
  • Hazard Statement:

    H302-H315-H319
  • Target:

    Integrin
  • Type:

    Peptides
  • Related Pathways:

    Cytoskeleton
  • Applications:

    COVID-19-immunoregulation
  • Field of Research:

    Metabolic Disease; Cardiovascular Disease
  • Assay Protocol:

    https://www.medchemexpress.com/GRGDSPK.html
  • Purity:

    98.12
  • Solubility:

    H2O
  • Smiles:

    O=C (N[C@@H] (CCCNC (N) =N) C (NCC (N[C@@H] (CC (O) =O) C (N[C@@H] (CO) C (N1[C@@H] (CCC1) C (N[C@@H] (CCCCN) C (O) =O) =O) =O) =O) =O) =O) CN
  • Molecular Formula:

    C28H49N11O11
  • Molecular Weight:

    715.76
  • Precautions:

    P264-P270-P280-P302+P352-P305+P351+P338-P330-P362+P364-P501
  • References & Citations:

    [1]Sessions BR, et al. Effects of amino acid substitutions in and around the arginine-glycine-aspartic acid (RGD) sequence on fertilization and parthenogenetic development in mature bovine oocytes. Mol Reprod Dev. 2006 May;73 (5) :651-7.|[2]G A Gronowicz, et al. Synthetic Peptide Containing Arg-Gly-Asp Inhibits Bone Formation and Resorption in a Mineralizing Organ Culture System of Fetal Rat Parietal Bones. J Bone Miner Res. 1994 Feb;9 (2) :193-201.|[3]Pierre-Henri Puech, et al. Measuring Cell Adhesion Forces of Primary Gastrulating Cells From Zebrafish Using Atomic Force Microscopy. J Cell Sci. 2005 Sep 15;118 (Pt 18) :4199-206.
  • Shipping Conditions:

    Blue Ice
  • Storage Conditions:

    -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
  • Scientific Category:

    Peptides
  • Clinical Information:

    No Development Reported
  • CAS Number:

    111119-28-9